U.S. Preeclampsia Laboratory Testing Market

The U.S. Preeclampsia Laboratory Testing Market is valued at USD 1.1 Bn in 2026 and is projected to reach USD 1.8 Bn,  growing at a CAGR of 6.70% by 2033.

Demand for Preeclampsia Laboratory Testing to Witness Healthy Revenue Growth by 2033

The U.S. preeclampsia laboratory testing market registered revenue worth US$1.1 Bn in 2025 and is set to exhibit robust revenue growth between 2026 and 2033. The market is poised to benefit from the rising burden of preeclampsia, coupled with investigational product launches that have been observed over the recent past. Fairfield Market Research indicates that the valuation of the U.S. preeclampsia laboratory testing market will rise at a healthy 6.70% CAGR during the period of assessment, reaching market value of US$1.8 Bn by the end of 2033.

Growing Health and Economic Burden Improves Scope for U.S. Preeclampsia Laboratory Testing Market

Preeclampsia is known to be a second leading cause of maternal mortality impacting fetal and infant health as well. It is also associated with the elevated risk of cardiovascular and metabolic diseases in both the mother and the child later in life. According to the Centres for Disease Control and Prevention, preeclampsia occurs in about 1 in 25 pregnancies in the U.S. Moreover, it’s also the cause of 15% of the premature births in the country. While the exact reason remains unknown, currently there neither seems to be a reliable test for predicting preeclampsia nor complete cure for the disease. The maternal and neonatal deaths, however, can be prevented with improved early diagnosis rate the early and gradually rising awareness about the same among general population.

The number of preeclampsia laboratory tests is on the rise. The U.S. is facing a severe challenge of growing health and economic burden. Preeclampsia Foundation states that short-term medical cost amounts to US$2.18 Bn to the U.S. healthcare system. The cost after the first 12 months of delivery is US$1.03 Bn, for maternal healthcare and US$1.15 Bn for infants born to mothers with preeclampsia. Mild and severe preeclampsia incidences are expected to contribute more or less equally to the market growth by the end forecast period. Severe preeclampsia type would register highest market growth by 2027 owing to an increase in the total rate of severe preeclampsia among delivery hospitalizations.

New Product Introductions and Research Collaborations and Fundings Augment Supply of Novel Diagnostic Products

New product launches and research collaborations are taking place in the preeclampsia diagnostics landscape at fast pace. Government & academic institutions are collaborating for better diagnostics and cure of preeclampsia. In early 2019, DiabetOmics, a U.S. based medical diagnostic company has launched a rapid point-of-care test ‘Lumella’ to estimate elevation of a protein biomarker in pregnant women with high risk of developing. Progenity, a women's health diagnostic firm recently announced the launch of preeclampsia rule-out test, called Preecludia^TM, and is expected to be commercialised soon.

According to a data published by the National Institutes of Health (NIH) in September 2018, several NIH institutes are investing into research on preeclampsia, with leading funders being the National Heart, Lung, and Blood Institute and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). Some other institutes currently funding for preeclampsia research comprise National Institute of General Medical Sciences, National Institute on Aging, National Institute on Minority Health and Health Disparities, National Institute of Allergy and Infectious diseases, and National Institute on Drug Abuse.

Blood Tests Witness Highest CAGR in U.S. Preeclampsia Laboratory Testing Market

Urine tests though lead the test type segment in terms of market value as well as volume, blood tests are anticipated to register a stronger growth rate due to need for early diagnosis and comparatively high accuracy against conventional urine tests.

Novel biomarkers are also hitting the market big time as is observed over the recent past. The collaboration of Thermo Fisher Scientific, Inc. with NX Prenatal is aiming to develop novel assays and non-invasive early detection systems enabling better evaluation of maternal and fetal biomarkers during pregnancy that correlate with adverse outcomes, such as preterm birth. Cell free RNA’s hold great promise in non-invasive diagnostics, though there is still a need for more detailed studies to map the signatures of these RNAs in disease pathogenesis and create disease-specific reference databases.

Diagnostic Centres to See Phenomenal Growth in U.S. Preeclampsia Laboratory Testing Market

Hospitals and clinics remain the largest revenue contributor in the U.S. for preeclampsia laboratory testing, followed by diagnostic centres. Use of novel biomarkers under study will lead to improved diagnostic assessment of preeclampsia with greater precision and accuracy. This development is expected to boost the diagnostic centres segment with highest growth rate by 2027. Also, strong presence and initiatives of several government and patient advocacy groups formed for the development of better diagnostics regimen, will further augment the market segment.

Decline in Fertility Rate and Delayed parenthood Act As Restraint for U.S. Preeclampsia Laboratory Testing Market

More number of women voluntarily opting out from parenthood, rise in infertility amongst women coupled with low birth rate will lead to overall decrease in preeclampsia incidences. This would lower the uptake of preeclampsia diagnostic tests and pose a challenge to the market growth. Numerous research studies are under evaluation showcasing effect of lifestyle and therapeutic interventions on reducing the risk of preeclampsia. This would further have a negative impact on the preeclampsia testing market.

U.S. Preeclampsia Laboratory Testing Market: Competitive Landscape

• DiabetOmics
• DRG Instruments GmbH
• F. Hoffmann-La Roche Ltd.
• GestVision, Inc.
• Lifeassay Diagnostics (Pty) Ltd.
• Metabolomic Diagnostics
• Perkin Elmer, Inc.
• Progenity, Inc.
• Quidel Corporation
• Siemens Healthineers
• Thermo Fisher Scientific, Inc.

The U.S. Preeclampsia Laboratory Testing Market is Segmented as Below:

By Test Type

• Urine Tests
• Blood Tests

By Preeclampsia Type

• Mild Preeclampsia
• Severe Preeclampsia

By End User

• Hospitals and Clinics
• Diagnostic Centres
• Others